The FDA has issued national priority vouchers to fast-track reviews of psilocybin for depression and methylone for PTSD, promising one- to two-month reviews once required trials conclude. Both drugs previously received "breakthrough therapy" designations. The agency also approved the first U.S. early-phase human study of ibogaine for alcohol use disorder. Officials say the move aims to accelerate access to promising therapies while maintaining rigorous scientific standards.
FDA Fast-Tracks Psilocybin and Methylone Reviews; First U.S. Ibogaine Trial Approved
The FDA Fast-Tracks Its Review of Psilocybin and Methylone, 2 Promising Psychedelics
Six days after President Donald Trump signed an executive order intended to accelerate regulatory reviews of investigational psychedelics, the Food and Drug Administration (FDA) announced it had issued "national priority vouchers" for two experimental therapies: psilocybin for depression and methylone (MDMC) for post-traumatic stress disorder (PTSD).
The vouchers follow earlier "breakthrough therapy" designations for both compounds and commit the agency to an "ultra-fast timeline" — an anticipated one-to-two month review window once the necessary studies are complete, compared with the more typical six months or longer.
What Officials Say
FDA Commissioner Marty Makary framed the move as part of a response to the nation's mental health crisis. He emphasized the promise of psychedelics for hard-to-treat conditions while stressing that development must be grounded in rigorous science and robust clinical evidence. In short, expedited review is intended to speed potential access but not at the expense of safety or data quality.
"Psychedelics have the potential to address the nation's mental health crisis, including conditions like treatment-resistant depression, alcoholism and other serious mental health and substance abuse conditions," Makary said.
Ongoing Clinical Programs
The FDA first recognized psilocybin as a breakthrough therapy in 2018 after early studies reported substantial improvements in people with treatment-resistant major depression and patients facing life-threatening illnesses. Several organizations are now pursuing late-stage trials:
- Compass Pathways (London) is conducting Phase 3 trials of a synthetic psilocybin formulation targeting treatment-resistant depression.
- Usona Institute (Madison, WI) is running a Phase 3 trial of psilocybin for major depressive disorder.
- Helus Pharma (formerly Cybin, Canada) is conducting Phase 3 studies of psilocin, the active metabolite of psilocybin, for the same indication.
Last year the FDA granted methylone breakthrough therapy status after a Phase 2 trial reported "rapid, robust, and durable improvements" in people with severe PTSD. New York City–based Transcend Therapeutics has moved into Phase 3 testing of methylone for PTSD.
Ibogaine Study And Broader Context
As part of the same push, the FDA approved an early-phase human study of ibogaine for alcohol use disorder — reportedly the first U.S.-approved human trial of the compound. Officials have described the administration's approach as "accelerating" research and review to enable responsible access to promising mental health treatments, including psychedelic therapies.
Advocates note that faster regulatory timelines can help bring therapies to market and focus discussions about insurance coverage and clinical infrastructure. Melissa Lavasani, founder and CEO of the Psychedelic Medicine Coalition, cautioned that development will still be gradual and iterative: expedited review shortens review time but does not eliminate the need for rigorous trials and real-world implementation planning.
Bottom Line
The FDA's national priority vouchers mark a significant step toward faster evaluation of promising psychedelic treatments, but regulators and researchers emphasize that speed must be matched by careful science, thorough trials, and attention to safety and access.
Help us improve.
